Biofil Chemicals & Pharmaceuticals Ltd

Biofil Chemicals & Pharmaceuticals Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 11 Sep 2026, driven primarily by a shift in technical indicators despite persistent fundamental weaknesses. The micro-cap pharmaceutical company’s Mojo Score improved to 37.0, reflecting a more optimistic technical outlook, even as valuation and financial trends remain challenging.

At Rs 37.75, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Biofil Chemicals & Pharmaceuticals Ltd locked at its upper circuit of 19.58% on 10 Sep 2026, with buyers queuing and no sellers willing to part with shares.

Biofil Chemicals & Pharmaceuticals Ltd has been downgraded from a Sell to a Strong Sell rating, reflecting deteriorating fundamentals and technical indicators. The downgrade, effective from 17 Aug 2026, is driven by a combination of worsening technical trends, stretched valuation metrics, flat financial performance, and weak quality scores, signalling caution for investors in this micro-cap pharmaceutical stock.

Biofil Chemicals & Pharmaceuticals Ltd has seen a marked shift in its valuation parameters, moving from a previously very attractive position to now being classified as very expensive. This change is underscored by a surge in its price-to-earnings (P/E) ratio to 109.85 and a price-to-book value (P/BV) of 2.45, significantly outpacing both historical averages and peer benchmarks within the Pharmaceuticals & Biotechnology sector.

Biofil Chemicals & Pharmaceuticals Ltd has seen its investment rating upgraded from Strong Sell to Sell, driven primarily by a shift in technical indicators despite persistent fundamental challenges. This nuanced change reflects a mildly improved technical outlook amid ongoing financial underperformance and valuation considerations within the Pharmaceuticals & Biotechnology sector.

Biofil Chemicals & Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 30 July 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 04 August 2026, providing investors with the latest insights into the company’s performance and outlook.

Biofil Chemicals & Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 22 July 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Biofil Chemicals & Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 10 July 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

Biofil Chemicals & Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 29 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Biofil Chemicals & Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 17 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Biofil Chemicals & Pharmaceuticals Ltd., a micro-cap pharmaceutical company with a market capitalisation of ₹57.00 crores, reported net profit of ₹0.21 crores in Q4 FY26 (Mar'26), marking a modest 5.00% increase year-on-year but a substantial 162.50% surge quarter-on-quarter. However, this apparent profitability improvement conceals deeper operational challenges, as the company's core business performance remains under significant pressure with volatile revenue patterns and contracting margins.

Biofil Chemicals & Pharmaceuticals Ltd has seen its investment rating upgraded from Strong Sell to Sell, reflecting a nuanced shift in its technical outlook and valuation metrics despite ongoing fundamental challenges. The upgrade, effective from 29 May 2026, is driven primarily by improved technical indicators and a more attractive valuation grade, while financial trends and quality scores remain subdued.

Biofil Chemicals & Pharmaceuticals Ltd has seen its investment rating upgraded from Sell to Strong Sell, driven primarily by shifts in technical indicators and valuation metrics. Despite persistent challenges in financial trends and quality fundamentals, the recent market performance and valuation adjustments have prompted this reassessment, signalling cautious investor sentiment amid mixed signals.

Biofil Chemicals & Pharmaceuticals Ltd has witnessed a notable shift in its valuation parameters, moving from a very attractive to an attractive rating, despite a challenging performance relative to the broader market. This change, driven primarily by adjustments in its price-to-earnings and price-to-book ratios, offers investors a fresh perspective on the stock’s price attractiveness within the Pharmaceuticals & Biotechnology sector.

At Rs 37.82, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Biofil Chemicals & Pharmaceuticals Ltd locked at its upper circuit of 19.99% on 26 May 2026, with buyers queuing and no sellers willing to part with shares.